NCT00932893 · MORE INFO

Limitations, agreements, and source contact

An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene · Source last updated 2017-01-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

other Details: Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

limitations And Caveats

description: No analyses of ALK fusion variants or protein expression were done due to limited slide stability of unstained tissue sections required for immunohistochemistry and no nucleic acid based assay was available to identify specific ALK gene fusion.

point Of Contact

email: ClinicalTrials.gov_Inquiries@pfizer.com
organization: Pfizer, Inc.
phone: 1-800-718-1021
title: Pfizer ClinicalTrials.gov Call Center

Complete source fields

certain Agreement

other Details: Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

limitations And Caveats

description: No analyses of ALK fusion variants or protein expression were done due to limited slide stability of unstained tissue sections required for immunohistochemistry and no nucleic acid based assay was available to identify specific ALK gene fusion.

point Of Contact

email: ClinicalTrials.gov_Inquiries@pfizer.com
organization: Pfizer, Inc.
phone: 1-800-718-1021
title: Pfizer ClinicalTrials.gov Call Center

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice